# QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Source: https://onco.cc/trials/nct07025239/  
OnCo record `nct07025239` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of QL1706, bevacizumab (glioblastoma use), fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07025239 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 430 participants, started 2025-07 and due to reach its primary completion in 2028-07. Interventions recorded: QL1706; Bevacizumab; Oxaliplatin; Capecitabine; Placebo. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression Free Survival (PFS) Assessed by the Independent Radiology Review Committee (IRRC). Colorectal eligibility wording from the registry: "* Unresectable metastatic colorectal adenocarcinoma confirmed by histopathology examination;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07025239
- Phase: 3
- Setting: A Randomized, Double-blind, Multicenter Phase 3 Study of QL1706 Injection in Combination With Bevacizumab and XELOX Versus Placebo in Combination With Bevacizumab and XELOX as First-line Therapy for the Treatment of Patients With Unresectable Metastatic Colorectal Cancer (mCRC)
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 430

## Sources

- ClinicalTrials.gov NCT07025239: https://clinicaltrials.gov/study/NCT07025239

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [QL1706](https://onco.cc/drugs/ql1706/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07025239.json